Current Status and Prospects of Targeted Therapy for Osteosarcoma

Zunguo Hu; Shuang Wen; Zijun Huo; Qing Wang; Jiantao Zhao; Zihao Wang; Yanchun Chen; Lingyun Zhang; Fenghua Zhou; Zhangyu Guo; Huancai Liu; Shuanhu Zhou

doi:10.3390/cells11213507

Current Status and Prospects of Targeted Therapy for Osteosarcoma

Cells. 2022 Nov 5;11(21):3507. doi: 10.3390/cells11213507.

Authors

Affiliations

¹ Department of Joint Surgery, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang 261061, China.
² Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.
³ Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.
⁴ Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Abstract

Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS prognosis is poor, and improving the survival of OS patients remains a challenge. Current treatment methods such as surgical approaches, chemotherapeutic drugs, and immunotherapeutic drugs remain ineffective. As research progresses, targeted therapy is gradually becoming irreplaceable. In this review, several treatment modalities for osteosarcoma, such as surgery, chemotherapy, and immunotherapy, are briefly described, followed by a discussion of targeted therapy, the important targets, and new technologies for osteosarcoma treatment.

Keywords: chemotherapy; osteosarcoma; surgical treatment; targeted therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Bone Neoplasms* / pathology
Bone and Bones / pathology
Humans
Immunologic Factors / therapeutic use
Molecular Targeted Therapy
Osteosarcoma* / pathology

Substances

Immunologic Factors

Grants and funding

This study was supported by the Shandong Province Natural Science Foundation of China (Grant No. ZR2016HM60 and ZR2019BH060), the Support Program for Youth Innovation Technology in Colleges and Universities of Shandong Province of China (Grant No. 2019KJK004), the Shandong Province Chinese Medicine Science and Technology Developmental Project (Grant No. 2019-0413), the Shandong Medical and Health Science and Technology Development Plan Project (Grant No. 2019WS606), the Gillian Reny Stepping Strong Center for Trauma Innovation, the Osteobiology Research Fund, and the Osteobiology Training Fund (to S.Z.).